Table 1.
Characteristics of Enrolled Patients at 2 Time Points of Specific Interest: Inclusion and After 50 Weeks of Follow-up
| Characteristic | No. (%) of Patients at Inclusion (n = 661) | No. (%) of Patients at Week 50 (n = 540) |
|---|---|---|
| Sex, male | 425 (64.3) | 355 (65.7) |
| Age, y, median (IQR) | 35 (30–41) | 35 (30–41) |
| BMI, kg/m2, median (IQR) | 16.7 (15.2–18.4) | 20.4 (18.8–22.2)a |
| CD4 count, cells/µL | ||
| Median (IQR) | 25 (10–56) | 199 (142–274)b |
| ≤50 | 475 (71.9) | 5 (0.9) |
| 51–200 | 186 (28.1) | 264 (48.9) |
| 201–350 | 0 (0) | 179 (33.1) |
| >350 | 0 (0) | 71 (13.2) |
| Missing | 0 (0) | 21 (3.9) |
| HIV RNA <2.4 log10 copies/mL | 0 (0) | 501 (96.2)c |
| Hemoglobin, g/dL, median (IQR) | 8.7 (7.1–10.3) | 13.4 (12.2–14.5)c |
| Treatment group | ||
| Early ART | 332 (50.2) | 281 (52.0) |
| Late ART | 329 (49.8) | 259 (48.0) |
| Temporarily lost to follow-up at week 50 | NA | 13 (2.4) |
| ART regimen | ||
| Stavudine-lamivudine-efavirenz | 0 (0) | 441 (81.7) |
| Other ART regimens | 0 (0) | 79 (14.6) |
| No ART | 661 (100.0) | 20 (3.7) |
| Cotrimoxazole prophylaxis | 644 (97.4) | 436 (80.7) |
| Fluconazole prophylaxis | 560 (84.7) | 245 (45.4) |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range; NA, not applicable.
a Available for 523 patients.
b Available for 519 patients.
c Available for 518 patients.